Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Plans secondary offering of 13 mil. shares of common stock with a portion of the shares to be offered in the U.S. and a portion overseas. An additional 1.95 mil. shares may be sold to cover overallotments. Net proceeds from the offering will be used to repay indebtedness under certain of the firm's revolving credit facilities incurred in connection with the purchase of Schneider Worldwide last September. The offering is being managed by Merrill Lynch, Paine Webber, Banc of America Securities LLC, Bear Stearns, Dain Rauscher Wessels, Deutsche Banc Alex. Brown, and U.S. Bancorp Piper Jaffray